In summary, these 12 AD individuals displayed lower CSF tau and pTau, higher CSF amyloid-β, and lower amyloid accumulation in the brain when compared to AD cases in community 2 (Fig. 3). The gene discussed is MAPT; the disease is Alzheimer disease.